Alaunos Therapeutics Inc
Follow $TCRT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TCRT by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TCRT moving today?
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TCRT overview
Related filings and maps
Congress activity in TCRT
No receipt-qualified Congressional disclosure is present for TCRT in the cached public ledger.
TCRT contract awards, year to date.
Public federal awards linked to this ticker.
TCRT lobbying filings, year to date.
Registered lobbying filings matched to Alaunos Therapeutics Inc.